Global Ticagrelor Market Size By Type (90 mg Tablet, 60 mg Tablet), By Application (Hospital Pharmacies, Retail Pharmacies), By Region, And Segment Forecasts, 2023 to 2032

The Global Ticagrelor Market was valued at USD 1.6 billion in 2023 and is projected to reach USD 3.1 billion by 2031, growing at a CAGR of 8.7% during the forecast period from 2023 to 2031. Ticagrelor, an oral antiplatelet medication used primarily for acute coronary syndrome (ACS) and to reduce the risk of thrombotic cardiovascular events, has become an integral part of cardiovascular disease management. Increasing prevalence of cardiovascular diseases, growing geriatric population, and rising awareness of preventive cardiovascular care are major drivers contributing to the growth of the ticagrelor market globally.

Drivers:

1. Rising Incidence of Cardiovascular Disorders:

The increasing global burden of heart disease, particularly ischemic heart conditions and myocardial infarctions, is propelling the demand for antiplatelet therapies such as ticagrelor. The growing adoption of dual antiplatelet therapy (DAPT) post-percutaneous coronary intervention (PCI) further supports market expansion.

2. Aging Population and Sedentary Lifestyles:

As the global population ages, the incidence of cardiovascular conditions rises correspondingly. Sedentary lifestyles, dietary habits, and increased comorbidity rates such as hypertension and diabetes amplify the demand for reliable therapeutic agents like ticagrelor.

3. Expanding Clinical Applications and Guidelines Support:

The inclusion of ticagrelor in international cardiovascular guidelines by bodies such as the American Heart Association (AHA) and the European Society of Cardiology (ESC) has boosted its adoption. Clinical evidence supporting superior efficacy compared to other P2Y12 inhibitors enhances its clinical preference.

Restraints:

1. High Cost and Limited Accessibility in Low-Income Regions:

Ticagrelor’s relatively higher cost compared to generic alternatives like clopidogrel can be a limiting factor, especially in low- and middle-income countries. Reimbursement challenges and healthcare budget constraints may impede broader adoption.

2. Risk of Adverse Effects and Drug Interactions:

Side effects such as bleeding, dyspnea, and drug-drug interactions may limit its use in certain patient populations, particularly among the elderly or those with renal/hepatic impairments.

Opportunity:

1. Expanding Emerging Market Penetration:

Developing healthcare infrastructure and improving awareness of advanced cardiovascular treatments in Asia-Pacific, Latin America, and parts of the Middle East and Africa present significant growth potential for ticagrelor manufacturers.

2. Patent Expiry and Entry of Generics:

As patents for branded ticagrelor formulations approach expiration, the emergence of cost-effective generic alternatives is expected to expand access and stimulate market growth in price-sensitive regions.

Market by System Type Insights:

By formulation, tablet-based ticagrelor remains the dominant system type in 2023, accounting for the majority of prescriptions due to ease of administration and high patient compliance. However, extended-release formulations under clinical development may offer future growth potential by improving dosage frequency and adherence.

Market by End-use Insights:

Hospitals led the market in 2023, driven by the critical role ticagrelor plays in post-acute coronary syndrome and PCI management. Retail pharmacies are expected to experience the fastest growth, fueled by increasing prescription volume for outpatient cardiovascular care and growing awareness among general practitioners and cardiologists.

Market by Regional Insights:

North America dominated the global ticagrelor market in 2023, owing to high healthcare spending, strong clinical awareness, and early adoption of novel therapies. Asia-Pacific is forecasted to witness the highest CAGR during the forecast period due to the rising incidence of heart disease, economic development, and healthcare access improvements in countries like China and India.

Competitive Scenario:

Key players operating in the global ticagrelor market include:

AstraZeneca PLC (original developer and key brand holder of Brilinta/Brilique)

Sun Pharmaceutical Industries Ltd.

Cipla Ltd.

Dr. Reddy’s Laboratories

Teva Pharmaceutical Industries Ltd.

Mylan N.V.

Torrent Pharmaceuticals Ltd.

These companies are focusing on strategic product launches, regulatory approvals, and geographic expansion. Notably, AstraZeneca continues to invest in expanding clinical indications, while generic entrants focus on pricing and distribution competitiveness.

Scope of Work – Global Ticagrelor Market

Key Market Developments:

2023: AstraZeneca expanded access programs for Brilinta in emerging markets, aiming to increase affordability.

2024: Multiple generic manufacturers, including Cipla and Teva, received tentative FDA approval for ticagrelor generics.

2025: Clinical trials began exploring ticagrelor’s efficacy in stroke prevention among high-risk patient cohorts.

FAQs:

1) What is the current market size of the Global Ticagrelor Market?

The market size in 2023 is USD 1.6 billion.

2) What is the major growth driver of the Global Ticagrelor Market?

The primary growth driver is the rising global burden of cardiovascular disease and the widespread use of ticagrelor in post-ACS management.

3) Which is the largest region during the forecast period in the Global Ticagrelor Market?

North America is the largest region due to high healthcare infrastructure and early adoption of new therapies.

4) Which segment accounted for the largest market share in the Global Ticagrelor Market?

The hospital segment accounted for the largest market share in 2023 due to ticagrelor’s role in inpatient cardiovascular treatment.

5) Who are the key market players in the Global Ticagrelor Market?

Key players include AstraZeneca PLC, Sun Pharma, Cipla, Teva, Dr. Reddy’s, and Mylan.